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by strong sexual dimorphism. Both enhancer of zeste homolog 2
(EZH2) and cell cycle-related kinase (CCRK) contribute to hep-
atocarcinogenesis, yet whether the two oncogenic factors have
functional crosstalk is unknown.
Methods: Cellular proliferation and tumorigenicity upon trans-
genic expression and RNA interferencewere determined by colony
formation and soft agar assays, xenograft, orthotopic and diethyl-
nitrosamine-induced HCC models. Gene regulation was assessed
by chromatin immunoprecipitation, site-directed mutagenesis,
luciferase reporter, co-immunoprecipitation and expression
analyses. Protein levels in clinical specimens were correlated with
clinicopathological parameters and patient survival rates.
Results: Ectopic CCRK expression in immortalized human liver
cells increased EZH2 and histone H3 lysine 27 trimethylation
(H3K27me3) to stimulate proliferation and tumor formation.
Conversely, knockdown of CCRK reduced EZH2/H3K27me3 levels
and decreased HCC cell growth, which could be rescued by EZH2
over-expression. Mechanistically, GSK-3b phosphorylation by
CCRK activated a b-catenin/TCF/E2F1/EZH2 transcriptional
feedback loop to epigenetically enhance androgen receptor (AR)Journal of Hepatology 20
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responsive element.AR and its subsequent transcriptional activation, thus forming a
self-reinforcing circuitry. Lentiviral-mediated knockdown of
CCRK, which abrogated the phosphorylation-transcriptional net-
work, prevented diethylnitrosamine-induced tumorigenicity.
More importantly, the hyperactivation of the CCRK-EZH2 cir-
cuitry in human HCCs correlated with tumor recurrence and poor
survival.
Conclusions: These ﬁndings uncover an epigenetic vicious cycle
in hepatocarcinogenesis that operates through reciprocal reg-
ulation of CCRK and EZH2, providing novel therapeutic strategy
for HCC.
 2014 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY-NC-ND license.Introduction
Hepatocellular carcinoma (HCC) is the ﬁfth most frequent malig-
nancy worldwide with a strong sexual dimorphism. Male to
female ratio averages between 2:1 and 7:1 in HCC associated
with viral infection and non-alcoholic fatty liver diseases [1,2].
Hepatitis B virus (HBV) infection accounts for about 60% of the
total liver cancer in developing countries. Unlike most other can-
cers, the incidence and mortality of HCC have increased in
Western countries in the past decade due to hepatitis C virus
infection and the obesity epidemic. Although the multikinase
inhibitor Sorafenib can improve survival of HCC patients, the
durability of treatment response is still far from satisfactory [3].
The alarmingly high failure rate of phase III molecular therapy tri-
als in the past 5 years further underscores the compelling need
for novel drug targets [4].
HCC pathogenesis is a complex process driven by accumulat-
ing genetic and epigenetic alterations [5,6]. Integrative oncoge-
nomic analysis has uncovered prominent oncogenes such as
CTNNB1, AKT, and E2F transcription factor 1 (E2F1) in HCC [7].
While these oncogenic pathways are often concordantly acti-
vated in molecular subtypes of human HCCs [8,9], the mechanis-
tic basis of the signaling connections is largely unknown.15 vol. 62 j 1100–1111
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Delineation of the signaling hubs that contribute to hepatocar-
cinogenesis may greatly advance therapeutic development [3,10].
One of the most remarkable discoveries in cancer genomics is
the recurrent somatic mutations of epigenetic-modifying genes
[11,12]. Although each HCC case has a unique mutational proﬁle,
up to 50% of cases are estimated to harbor mutations in different
chromatin regulators [4,10,13]. Enhancer of zeste homolog 2
(EZH2), a subunit of Polycomb repressive complex 2 (PRC2) that
catalyzes the repressive histone H3 lysine 27 trimethylation
(H3K27me3) [14], is subject to genetic alteration in hematologi-
cal malignancies and over-expression in a wide range of solid
tumors including HCC [12,15]. Numerous evidence have sug-
gested that aberrations of EZH2 represent early events that ren-
der cells susceptible to oncogenic transformation and refractory
to differentiation program [15,16]. However, the mechanisms
governing the over-expression and functions of this master chro-
matin regulator in HCC remain elusive.
Concordant with the male predominance of HCC, the sex hor-
mone receptor androgen receptor (AR) plays a dominant role in
hepatocarcinogenesis [17]. Our prior work underpinned cell
cycle-related kinase (CCRK, also known as cyclin-dependent
kinase 20) as an oncogenic effector of AR in HCC [18,19].
Despite its strong oncogenicity, no study has explored the epige-
netic regulation by CCRK. Here we show that CCRK induces EZH2
up-regulation and phosphorylation in an epigenetic circuitry con-
sisting of glycogen synthase kinase 3b (GSK-3b), b-catenin, T-cell
factor (TCF), E2F1, AKT, and AR. This signaling network is activated
during diethylnitrosamine (DEN)-induced hepatic tumorigenicity
which can be dramatically suppressed by lentiviral-mediated
knockdown of CCRK. As the self-reinforcing circuit hyperactivates
in human hepatocarcinogenesis and associates with poor prog-
nosis of patients, our data raise the possibility that CCRK is a
promising molecular target for therapeutic intervention.Materials and methods
Cell culture, transfection and functional assays
LO2, HuH7, PLC5, and SK-Hep1 cells were cultured in DMEM supplemented with
10% FBS (Hyclone). Cell transfection was conducted using X-tremeGene
Transfection Reagent (Roche) or HiPerfect (Qiagen) according to the manufac-
turer’s instructions. The information of small-interfering RNA (siRNA), short-hair-
pin RNA (shRNA) constructs, expression vectors, and luciferase reporter
constructs are described in the Supplementary material. Anchorage-dependent
and independent growth were analyzed by colony formation and soft agar assays,
respectively, as previously described [18].
Quantitative RT-PCR, ChIP-PCR, immunoblotting, co-immunoprecipitation and
immunohistochemistry
cDNA synthesis from RNA puriﬁed from cell lines and mouse samples was
conducted using reverse transcription (RT) Master Kit (Invitrogen). Chromatin
immunoprecipitation (ChIP) assays were performed as previously
described [18,20]. Detailed protocols of quantitative RT-PCR, ChIP-PCR, cell
lysis, immunoblotting and co-immunoprecipitation are described in the
Supplementary material. Cell proliferation in mouse tissues was assayed by Ki67
immunohistochemistry as previously described [19].
In vivo tumorigenicity assays
The xenograft and orthotopic models were performed using athymic nude mice
(n = 7 per group) as previously described [18]. The CCRK knockdown experiment
in the DEN (2 mg/kg; Sigma-Aldrich) model was performed using male C57BL/6
mice (n = 12 per group) as previously described [19]. Lentiviruses encodingJournal of Hepatology 2015shRNA against CCRK or a control sequence were packaged according to the manu-
facturer’s instructions (Dharmacon). All animal studies were reviewed and
approved by the Animal Experimentation Ethics Committee of the Chinese
University of Hong Kong.
Patients samples
Patients who underwent hepatectomy for HCC at the Prince of Wales Hospital
(Hong Kong) were included in this study. All patients gave written informed con-
sent on the use of clinical specimens for research purposes. Studies using human
tissue were reviewed and approved by the Joint CUHK-NTEC Clinical Research
Ethics Committee.
Statistical analysis
Unless otherwise indicated, data are presented as mean ± standard deviation of
three independent experiments. Statistical analysis is described in the
Supplementary material. A two tailed p value of less than 0.05 was considered
statistically signiﬁcant.Results
EZH2 is required for CCRK-induced hepatocellular proliferation and
transformation
To investigate the role and function of EZH2 in CCRK-induced hep-
atocarcinogenesis,wemodulated gene expressions and performed
colony formation and soft agar assays using both ectopic expres-
sion and knockdown approaches. Ectopic CCRK expression
induced EZH2 and global H3K27me3 levels (Fig. 1A, left) and
markedly increased focus formation (Fig. 1A, right) and
anchorage-independent growth (Fig. 1B) of LO2 cells, an immor-
talized human liver cell line [18]. Notably, silencing of EZH2 by
shRNA abrogated the induced proliferation and malignant trans-
formation in CCRK-expressing cells (Fig. 1A–B). Conversely,
shRNA-mediated knockdown of CCRK in PLC5 HCC cells dramati-
cally reduced EZH2 and H3K27me3 levels (Fig. 1C, left) and
decreased anchorage-dependent (Fig. 1C, right) and -independent
growth (Fig. 1D), which could be rescued by ectopic EZH2 expres-
sion (Fig. 1C–D). Consistently, downregulation of EZH2 in PLC5
and HuH7 HCC cells also resulted in signiﬁcant growth inhibition
(Supplementary Fig. 1A–B). We next performed in vivo experi-
ments to validate the functional relationship between CCRK and
EZH2. CCRK stably-transfected LO2 cells (CCRK-shCtrl-LO2)
displayed signiﬁcant increase in tumor volume and weight in
the xenograft model when compared with empty vector-
transfected cells (Vec-shCtrl-LO2), whereas knockdown of EZH2
completely attenuated the tumorigenicity of CCRK-shEZH2-LO2
cells (Fig. 1E). Concordantly, in an orthotopic model where the
stable cell xenografts were implanted into the recipient livers,
CCRK-induced intrahepatic tumorigenicity was abolished by
EZH2 knockdown (Fig. 1F). These results demonstrate that EZH2
upregulation is required for CCRK-induced hepatocarcinogenesis.
CCRK activates a GSK-3b/b-catenin/TCF/E2F1 cascade to upregulate
EZH2
We have recently identiﬁed GSK-3b as a CCRK kinase target
which mediates b-catenin activation in liver and HCC cells
[18,19]. To elucidate whether the GSK-3b/b-catenin signaling is
involved in CCRK-induced EZH2 upregulation, we ﬁrst employed
a kinase-defective (KD) CCRK mutant whose Thr161 active site
was replaced by alanine (T161A). Ectopic expression of wild-typevol. 62 j 1100–1111 1101
C D
E
F
Vector
CCRK
shCtrl
shEZH2
CCRK
EZH2
H3K27me3
β-actin
+
+ +
+ +
+
- -
-
-
- -
LO2
PLC5
shCtrl
shCCRK
Vector
EZH2
CCRK
EZH2
H3K27me3
β-actin
+
+ +
+ +
+
- -
-
-
- -
LO2
PLC5
N
o.
 o
f c
ol
on
ie
s
shEZH2
CCRK + +-
+--
300
250
200
150
100
50
0
*** ***
*** ***
*** ***
*** **
shEZH2
CCRK + +-
+--
+ +-
+--EZH2
shCCRK + +-
+-- EZH2
shCCRK
N
o.
 o
f c
ol
on
ie
s
N
o.
 o
f c
ol
on
ie
s
N
o.
 o
f c
ol
on
ie
s
PLC5
LO2
Vec + shCtrl
CCRK + shCtrl
CCRK + shEZH2
shCtrl + Vec
shCCRK + Vec
shCCRK + EZH2
shCtrl + Vec
shCCRK + Vec
shCCRK + EZH2
Vec + shCtrl
CCRK + shCtrl
CCRK + shEZH2
120
100
80
60
40
20
0
100
80
60
40
20
0
140
120
100
80
60
40
20
0
Xe
no
gr
af
t m
od
el
CCRK
EZH2
H3K27me3
β-actin
CCRK
EZH2
H3K27me3
β-actin
O
rt
ho
gr
af
t m
od
el
Tu
m
or
 v
ol
um
e 
(m
m
3 )
Tu
m
or
 v
ol
um
e 
(m
m
3 )
Tu
m
or
 w
ei
gh
t (
m
g)
Tu
m
or
 w
ei
gh
t (
m
g)
160
140
120
100
80
60
40
20
0
********
**** ******1000
800
600
400
200
0
1200
1000
800
600
400
200
0
140
120
100
80
60
40
20
0
Vec-shCtrl CCRK-shCtrl CCRK-shEZH2Vec-shCtrl-
LO2
CCRK-shCtrl-
LO2
CCRK-shEZH2-
LO2
A B
Vec-shCtrl-
LO2
CCRK-shCtrl-
LO2
CCRK-shEZH2-
LO2
Fig. 1. EZH2 is required for CCRK-induced hepatocellular proliferation and transformation. (A) Immunoblot analysis of CCRK, EZH2, and H3K27me3 expression (left),
focus formation (right), and (B) anchorage-independent growth in control and CCRK-expressing LO2 cells with or without EZH2 knockdown. (C and D) Same experiments
for control and CCRK-silencing PLC5 cells with or without EZH2 over-expression. (E) Tumorigenicity of control and CCRK-expressing LO2 cells with or without EZH2
knockdown were determined by xenograft and (F) orthotopic mouse models (n = 7 per group). Immunoblot analysis of CCRK, EZH2, H3K27me3 expression and
representative images of the tumors in each group are shown. Tumor volume and weight of the excised tumors in the three groups were measured. ⁄⁄p <0.01; ⁄⁄⁄p <0.001.
(This ﬁgure appears in color on the web.)
Research Article(WT) but not KD CCRK induced an upregulation in EZH2 and
H3K27me3 levels in both LO2 liver and SK-Hep1 HCC cells, which
was associated with increased GSK-3b phosphorylation at serine9
(p-GSK3bSer9) and active b-catenin level (Fig. 2A, left). Moreover,
inhibition of p-GSK3bSer9 by a dominant-inhibitory S9A-GSK-3b
mutant impaired not only CCRK-induced b-catenin activation,
but also EZH2 and H3K27me3 (Fig. 2A, right). To determine the
role of b-catenin signaling, we ablated b-catenin by shRNA or
expressed dominant-negative TCF (dnTCF) in CCRK-expressing
LO2 cells. Blockage of b-catenin/TCF signaling dramatically
reduced CCRK-induced EZH2 and H3K27me3 levels (Fig. 2B).
Moreover, CCRK increased the expression of E2F1, an EZH2
trans-activator [21] in a GSK-3b/b-catenin/TCF-dependent man-
ner (Fig. 2A–B). WT but not KD CCRK induced b-catenin occu-
pancy (Fig. 2C, left) to drive E2F1 transcription, as deletion of
TCF binding site rendered the E2F1 promoter non-responsive to
CCRK induction (Fig. 2C, right). Further, knockdown of E2F1 by
two independent siRNAs abrogated CCRK-induced E2F1 binding
to EZH2 promoter and EZH2/H3K27me3 expression levels1102 Journal of Hepatology 2015(Fig. 2D; Supplementary Fig. 2A). Accordingly, WT but not KD
CCRK induced E2F1 promoter binding (Fig. 2E, left) to activate
EZH2 transcription, because deletion of both E2F1 binding sites
in the EZH2 promoter abolished transcriptional activation by
CCRK (Fig. 2E, right).
We further conﬁrmed these results by two HCC cell lines,
namely the CCRK-low-expressing SK-Hep1 cells and the
CCRK-highly-expressing PLC5 cells using over-expression
(Supplementary Fig. 3A–D) and knockdown approaches, respec-
tively. Knockdown of CCRK in PLC5 cells dramatically reduced b-
catenin signaling and the levels of E2F1, EZH2, and H3K27me3,
which were restored by ectopic expression of dominant-positive
b-catenin (dpb-catenin) or TCF (dpTCF) (Fig. 2F, left). Moreover,
both dpb-catenin and dpTCF alleviated the shCCRK-mediated
suppression of b-catenin and E2F1 binding to E2F1 and EZH2
promoters, respectively (Fig. 2F, right). Taken together, these
ﬁndings demonstrate that CCRK phosphorylates GSK-3b to
activate a b-catenin/TCF/E2F1 transcriptional cascade for EZH2
up-regulation.vol. 62 j 1100–1111
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CCRK induces a b-catenin/E2F1/EZH2 transcriptional feedback loop
via PRC2-mediated silencing
We next examined whether CCRK induces EZH2-mediated epige-
netic silencing. Consistent with our previous ﬁnding that EZH2
effectively silences Wnt antagonists via H3K27me3 in HCC [20],
quantitative ChIP-PCR showed that CCRK induced EZH2 promoter
occupancy on AXIN2, NKD1, PPP2R2B, PRICKLE1, and SFRP5 in both
LO2 and SK-Hep1 cells (Fig. 3A). Moreover, CCRK induced pro-
moter occupancy of another PRC2 component SUZ12 and the
repressive H3K27me3 but not the active H3K4me3 mark
(Fig. 3A). In contrast, the KD CCRK mutant, which was unable
to upregulate EZH2 (Fig. 2A), failed to induce PRC2 and
H3K27me3 occupancy on these promoters (Fig. 3A). In accord,
quantitative RT-PCR showed that WT but not KD CCRK signiﬁ-
cantly reduced the mRNA expression of these Wnt antagonists
(Fig. 3B). On the other hand, downregulation of EZH2 by shRNA
in PLC5 cells reduced H3K27me3, active b-catenin and E2F1
levels (Supplementary Fig. 2B). Moreover, shEZH2 decreased b-
catenin and E2F1 binding to E2F1 and EZH2 promoters, respec-
tively (Supplementary Fig. 2C). These ﬁndings demonstrate that
CCRK induces PRC2-mediated silencing to activate a b-catenin/
E2F1/EZH2 transcriptional feedback loop.
EZH2 feedback induces CCRK expression via activation of b-catenin/
AR signaling
Based on the crosstalk between AR, b-catenin and EZH2 signaling
[18,20], we hypothesized that EZH2 epigenetically regulates AR
signaling through b-catenin activation. Ectopic expression of
WT EZH2 increased the H3K27me3 levels and expressions of
AR, AR phosphorylation at serine81 (p-ARSer81) and CCRK in both
LO2 and SK-Hep1 cells, indicating induction of AR transcriptional
activity by EZH2 (Fig. 3C). As expected, EZH2 also increased active
b-catenin level in consensus with repression of the Wnt
antagonists (Fig. 3C–D). In contrast, ectopic expression of EZH2
mutant without SET domain (EZH2 DSET), which was unable to
trimethylate H3K27, failed to repress Wnt antagonists and acti-
vate b-catenin and AR signaling (Fig. 3C–D). Notably, inhibition
of b-catenin/TCF signaling by shb-catenin or dnTCF abolished
EZH2-induced AR, p-ARSer81, CCRK expressions (Fig. 3E, left) and
AR-responsive transcriptional activity in LO2 cells (Fig. 3E, right).
In the reciprocal experiments, ectopic expression of dpb-catenin
or dpTCF in EZH2 knockdown PLC5 cells restored the AR
transcriptional activity and CCRK upregulation (Fig. 3F). In
accordance with our data above, downregulation of b-catenin in
HCC cells not only reduced the AR transcriptional activity and
CCRK expression but also the EZH2 and H3K27me3 levelsFig. 2. CCRK upregulates EZH2 expression through activation of a GSK3b/b-catenin/TC
total b-catenin, E2F1, EZH2, and H3K27me3 in LO2 and SK-Hep1 cells expressing WT and
vector control (right). (B) Immunoblot analysis of CCRK, active and total b-catenin, Flag-ta
in control and CCRK-expressing LO2 cells with or without shb-catenin and dnTCF expres
control, WT and KD CCRK-expressing LO2 cells (left). Enrichment was determined as a pe
the E2F1 promoter luciferase reporter with or without TCF binding site deletion in CCRK-
control and CCRK-expressing LO2 cells with or without E2F1 knockdown by two indepen
in control, WT and KD CCRK-expressing LO2 cells (left). The activity of the EZH2 promote
CCRK-expressing LO2 cells (right). (F) Immunoblot and quantitative RT-PCR analyses in
expression (left). Quantitative ChIP-PCR analysis of b-catenin and E2F1 binding on E2F1 a
without dpb-catenin and dpTCF expression (right).
1104 Journal of Hepatology 2015(Supplementary Fig. 4A–B). In addition, rescue experiments have
shown that AR increases EZH2 and H3K27me3 levels in a
CCRK-dependent manner (Supplementary Fig. 5A–B). Overall,
these data decipher a critical epigenetic component of the CCRK
auto-regulatory loop.
AKT-mediated EZH2 phosphorylation is indispensable for the CCRK
auto-regulatory loop
Recent studies unveiled the polycomb-independent role of EZH2
in gene activation via AKT-mediated phosphorylation [22,23].
Interestingly, we found that ectopic expression of WT but not
KD CCRK induced both AKT phosphorylation at serine473 (p-
AKTSer473) and EZH2 phosphorylation at serine21 (p-EZH2Ser21)
in LO2 and SK-Hep1 cells (Fig. 4A). Over-expression of an AKT
S473A mutant, which lacks a phosphorylation site in the
hydrophobic motif, abolished CCRK-induced p-EZH2Ser21 without
affecting the total EZH2 and H3K27me3 levels (Fig. 4B). To further
investigate the role of p-EZH2Ser21 in the AR/CCRK cascade, we
expressed WT EZH2 and the S21A mutant in LO2 and SK-Hep1
cells. In contrast to the Ser21 phosphorylation-competent EZH2,
the S21A mutant failed to upregulate AR and CCRK expressions
(Fig. 4C, left) and the CCRK promoter activity (Fig. 4C, right).
p-EZH2Ser21-AR interaction is required forCCRKpromoterco-occupancy
and transcriptional activation
We next determined how EZH2 phosphorylation regulates CCRK
transcription. Ectopic CCRK expression increased AR, EZH2 and
p-EZH2Ser21 expression (Fig. 4D, top) and induced its own tran-
scription as shown by promoter luciferase assays in both LO2
and SK-Hep1 cells (Fig. 4D, bottom). Notably, knockdown of
either AR or EZH2 in CCRK-expressing cells completely abolished
CCRK auto-regulation (Fig. 4D). Deletion of the androgen-re-
sponsive element (ARE) in the CCRK promoter [18] prevented
the transcriptional activation, indicating that the transcription
was dependent on direct AR binding (Fig. 4D). Quantitative
ChIP-PCR indeed conﬁrmed that CCRK induced its own promoter
occupancy by AR, EZH2 and p-EZH2Ser21 in both cell lines
(Fig. 4E). In accordance with gene activation, CCRK increased
the binding of RNA polymerase II with the active H3K4me3
but not repressive H3K27me3 mark to its promoter (Fig. 4E).
In contrast, downregulation of either AR or EZH2 abrogated their
promoter co-occupancy and the active chromatin state induced
by CCRK (Fig. 4E).
We next conducted co-immunoprecipitation to determine
whether AR physically interacts with EZH2 or p-EZH2Ser21 for
promoter co-occupancy. WT but not KD CCRK induced a robustF/E2F1 cascade. (A) Immunoblot analysis of CCRK, p-GSK3bSer9, GSK-3b, active and
KD CCRK (left), or WT CCRK with or without S9A-GSK3bmutant compared to the
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sion. (C) Quantitative ChIP-PCR analysis of b-catenin binding on E2F1 promoter in
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expressing LO2 cells (right). (D) Immunoblot and quantitative RT-PCR analyses in
dent siRNAs. (E) Quantitative ChIP-PCR analysis of E2F1 binding on EZH2 promoter
r luciferase reporter with or without single or double E2F1-binding site deletion in
control and CCRK-silencing PLC5 cells with or without dpb-catenin and dpTCF
nd EZH2 promoters, respectively, in control and CCRK-silencing PLC5 cells with or
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JOURNAL OF HEPATOLOGYphysical interaction between AR and EZH2/p-EZH2Ser21 in LO2
and SK-Hep1 cells (Fig. 4F, left). However, co-expression of WT
CCRK with either EZH2 S21A (Fig. 4F, middle) or AKT S473A
mutant (Fig. 4F, right), which prohibited p-EZH2Ser21 (Fig. 4B),Journal of Hepatology 2015abolished the interaction even though both AR and EZH2
remained upregulated. These data demonstrate that CCRK
mediated p-EZH2Ser21, but not un-phosphorylated EZH2, is essen-
tial for its interaction with AR.vol. 62 j 1100–1111 1105
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Research ArticleThe CCRK-EZH2 circuitry is activated during HCC development in
mice
According to the in vitro data, CCRK and EZH2 form an epigenetic
circuitry to stimulate hepatocellular proliferation and trans-
formation. To validate the functional signiﬁcance of the CCRK-
EZH2 circuitry in vivo, we investigated whether it is perturbed
during the development of DEN-induced hepatocarcinogenesis,
a murine HCC model reminiscent of patients with poor survival
[24]. At 8 months post-treatment, DEN-induced HCCs displayed
aberrant expressions of AR, p-ARSer81, CCRK, p-GSK3bSer9, active
b-catenin, E2F1, p-AKTSer473, p-EZH2Ser21, EZH2, and H3K27me3
when compared to the adjacent non-tumoral tissues and normal
livers of the untreated mice (Fig. 5A, top; Supplementary Fig. 6).
In addition, the transcript levels of Ar, Ccrk, E2f1, and Ezh2 were
low in control liver tissues but highly elevated in tumors
(Fig. 5A, bottom). In contrast, the expressions of the Wnt antago-
nists Axin2, Nkd1, Ppp2r2b, Prickle1, and Sfrp5 were strongly
repressed in tumors compared to control liver tissues (Fig. 5A,
bottom). Notably, the aberrations of the transcript and protein
levels of the CCRK-EZH2 circuit members were already evident
at 6 month old DEN-treated mice before visible tumors were1106 Journal of Hepatology 2015detected, suggesting that it was an early carcinogenic event
(Fig. 5A).
Suppression of CCRK abrogates the circuitry to prevent hepatocar-
cinogenesis
To investigate whether perturbation of the CCRK-EZH2 circuitry
affects HCC development, we tested if lentiviral-mediated silenc-
ing of CCRK can suppress tumor growth in the DEN-induced HCC
model. Knockdown of CCRK signiﬁcantly decreased the liver to
body weight (p <0.05; Fig. 5B) and more importantly >70% tumor
numbers in DEN-treated mice (p <0.01; Fig. 5C). Both tumor vol-
ume and weight in CCRK-silencing livers were also signiﬁcantly
decreased by >4-fold when compared to control livers (p <0.05
and p <0.01; Fig. 5D). Immunohistochemical staining of Ki67-
positive tumor cells in CCRK-silencing livers was 3-fold less than
that in control livers (p <0.001; Fig. 5E), indicating inhibition of
aberrant hepatocellular proliferation by CCRK knockdown. The
reduced tumorigenicity in DEN-treated mice was accompanied
by suppression of the AR, p-ARSer81, CCRK, p-GSK3bSer9, active
b-catenin, E2F1, p-AKTSer473, p-EZH2Ser21, EZH2, and H3K27me3
levels (Fig. 5F, top) as well as transcriptional repression andvol. 62 j 1100–1111
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JOURNAL OF HEPATOLOGYupregulation of the oncogenic factors and Wnt antagonists,
respectively (p <0.001; Fig. 5F, bottom). Taken together, these
data demonstrate that CCRK-EZH2 circuit activation is essential
for HCC development in vivo.
The CCRK-EZH2 circuit components are concordantly over-expressed
in human HCC tissues
To investigate the clinical relevance of our ﬁndings, the protein
levels of AR, p-ARSer81, CCRK, p-GSK3bSer9, active b-catenin,
E2F1, p-AKTSer473, p-EZH2Ser21, EZH2, and H3K27me3 were exam-
ined in 34 pairs of human HCC tumor/non-tumor and 5 normal
liver tissues. In contrast to the low basal levels in normal liver
controls, marked upregulation of all protein expressions were
observed in HCC tissues (Fig. 6A). Their average fold-changes of
expressions in tumor tissues were also signiﬁcantly higher than
those of the paired non-tumor tissues (p <0.001; Fig. 6B). In the
same cohort of samples, we examined the correlations between
the expression levels among different circuit components.
Notably, positive correlations between; (1) AR and p-ARSer81,
(2) p-ARSer81 and CCRK, (3) CCRK and p-GSK3bSer9, (4)
p-GSK3bSer9 and active b-catenin, (5) active b-catenin and E2F1,
(6) E2F1 and EZH2, (7) EZH2 and H3K27me3, (8) active b-catenin
and AR, (9) CCRK and p-AKTSer473 as well as (10) p-AKTSer473, and
p-EZH2Ser21 revealed a corresponding over-expression in humanJournal of Hepatology 2015HCCs (Pearson’s correlation coefﬁcients: r = 0.785–0.906;
p <0.001; Fig. 6C–D). Moreover, stepwise increases in protein
expressions were observed along hepatocarcinogenesis, namely
normal livers to adjacent precancerous liver tissues to HCC
tumors (Fig. 6C). Interestingly, we found that the circuit compo-
nents exhibited higher expressions in both male precancerous
liver and HCC tissues compared to the female counterparts as
shown in the Western blots (Fig. 6A) and the correlation graphs
(Fig. 6C).
Hyperactivation of the CCRK-EZH2 circuitry correlates with poor
prognosis of patients
We investigated if the CCRK-EZH2 circuitry is perturbed during
HCC progression. We found that the protein expression levels
of all the circuit components were increased from early to
intermediate/advanced stages of HCC (p <0.05; Fig. 7A).
Moreover, their expressions were higher in poorly-differentiated
than moderately- or well-differentiated HCCs (p <0.05 to 0.01;
Fig. 7B). Finally, we determined whether the activity of the
CCRK-EZH2 circuitry associates with HCC prognosis. The activity
was determined by the averaged fold-change of all circuit compo-
nent expressions in tumor vs. non-tumor tissues (Supplementary
Table 1). Hyperactivation of the CCRK-EZH2 circuitry was
signiﬁcantly associated with reduced serum albumin level, poorvol. 62 j 1100–1111 1107
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Research Articledifferentiation and recurrence of HCC (p <0.05; Supplementary
Table 2). Most strikingly, Kaplan-Meier analysis showed that
HCC patients with high circuit activity were signiﬁcantly
associated with shorter overall (hazard ratio = 20.99, p <0.0001;
Fig. 7C) and disease-free survival rates (hazard ratio = 6.04,
p <0.01; Fig. 7D).Discussion
Accumulating evidence has unmasked the molecular linkage
between sex hormone signaling and gender disparity in HCC
incidence [25–27]. Although aberrant chromatin modiﬁcations1108 Journal of Hepatology 2015and remodeling have emerged as hallmarks of the male-
predominant HCC [4,6,13], whether mechanistic links exist
between chromatin regulator and AR signaling have yet to be
delineated. Our data reveal a tumor-initiating circuitry
constituted by the reciprocal regulation of CCRK and EZH2. The
dual kinase activities of CCRK regulate the transcription and
post-translation of EZH2. The histone methyltransferase and
co-activator functions of EZH2 in turn upregulate AR expression
and transcriptional activity, respectively, to trans-activate CCRK,
thus establishing an epigenetic vicious cycle (Fig. 6D).
Epigenetic switches mediated by microRNA transcription factor
regulatory loops play critical roles in HCC initiation [28,29]. In
the context of AR-induced hepatocarcinogenesis, we propose avol. 62 j 1100–1111
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JOURNAL OF HEPATOLOGYmodel of epigenetic circuitry in which transient androgen/AR
signaling is converted to a continuous signal by EZH2 activities.
Downregulation of EZH2 abolishes the pro-proliferative and
malignant transformation functions of CCRK, mechanistically
linking epigenetic reprogramming and liver cancer. The gender
difference expression pattern of the CCRK-EZH2 circuit members
in human HCCs further corroborates the biological signiﬁcance of
this self-reinforcing circuitry in male hepatocarcinogenesis.
It is becoming increasingly clear that oncogenic proteins
interact through feedback and feed-forward loops in complex sig-
naling networks [30]. Our data suggests that CCRK functions as a
signaling hub to connect multiple kinases (GSK-3b and AKT) and
transcriptional regulators (AR, b-catenin, TCF, E2F1, EZH2) which
play critical roles in HCC pathogenesis [2,3,7]. Intriguingly, a
positive feedback loop is identiﬁed within this phosphorylation-
transcriptional network, whereby a GSK-3b/b-catenin/TCF/E2F1
cascade trans-activates EZH2, which binds to and represses the
promoters of Wnt antagonists via PRC2-mediated H3K27me3,
leading to increased b-catenin/TCF and E2F1 transcriptional
activities. Such ‘wheel within a wheel’ mechanism provides addi-
tional epigenetic input into b-catenin/TCF-mediated transcription
to maintain preferentially high AR expression in HCC.
In addition to the transcriptional feedback loop, we also
identiﬁed a feed-forward loop in which CCRK induces EZH2
phosphorylation, thereby promoting p-EZH2Ser21-AR physical
interaction for CCRK promoter co-occupancy and transcriptional
activation. Contrary to the H3K27me3-mediated repression of
the Wnt antagonists, phosphorylated EZH2 functions as an AR
co-activator to establish an active chromatin state at the CCRK
promoter that is accessible to RNA polymerase II. While the SET
domain is required for epigenetic activation of b-catenin signal-
ing, serine21 phosphorylation of EZH2 may also contribute to
AR induction via facilitating complex formation and promoterJournal of Hepatology 2015binding with b-catenin (data not shown). Our ﬁndings suggest
that AKT is a new oncogenic mediator of CCRK and strengthens
the notion that AKT-mediated EZH2 phosphorylation at serine21
is a critical modiﬁcation for its PRC2-independent functions in
prostate and brain cancers [22,23,31]. While CCRK has also been
shown to promote the male-predominant glioblastoma [32], the
interplay between CCRK and EZH2 pathways in this cancer war-
rants further investigation. Taken together, our ﬁndings suggest
that CCRK-activated GSK-3b and AKT phosphorylation endorse
EZH2 targeting of both histone and non-histone substrates,
respectively, to contribute to the transcriptional program in HCC.
As hundreds of millions of people worldwide are still at a high
risk of new HCC development due to viral infection and obesity,
the deﬁnition of molecular aberrations suitable for prevention
is especially important in this malignancy. Our recent ﬁnding of
CCRK mediating the viral-host interaction in HBV-associated
HCC [19] suggests its involvement in the early carcinogenic pro-
cess. We found that the HBV X oncoprotein augments a CCRK/
GSK-3b/b-catenin/AR regulatory loop in which its feedback
upregulates its own expression to promote hepatocellular
proliferation and transformation [19]. In this study, we further
delineated an essential epigenetic component of the molecular
circuitry and showed that activation of this vicious cycle precedes
the formation of tumors in DEN-treated mice. More importantly,
expression analysis of the clinical specimens revealed signiﬁcant
stepwise increases of the CCRK-EZH2 circuit components along
the carcinogenic cascade. Using a similar DEN-treated model
and a cohort of patient samples, He et al. have recently identiﬁed
HCC progenitor cells in the premalignant lesions [33]. Autocrine
interleukin-6 signaling, which constitutes the inﬂammatory feed-
back circuits [28,29], plays a pivotal role for the transformation of
these HCC progenitors [33]. Delineating the potential molecular
connection between the CCRK-EZH2 and inﬂammatory circuitsvol. 62 j 1100–1111 1109
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may provide further insights into HCC initiation and prevention
strategies.
Our clinical data demonstrate that the CCRK-EZH2 circuitry is
important not only for HCC initiation but also progression. In a
relatively small cohort of human HCCs, over-expression of the
CCRK-EZH2 circuit members is observed, which signiﬁcantly
correlates with tumor recurrence and poor survival of patients.
The rare commonality of actionable mutations between individ-
ual HCC cases raises the possibility that alteration of ‘epi-driver
genes’ may be an alternative ‘Achilles heel’ in liver cancer
[10,11]. Silencing of CCRK dephosphorylates the kinases,
suppresses the transcriptional regulators and perturbs their
downstream targets in vivo, thus supporting its central role in
regulating the phosphorylation-transcriptional network. The
dramatic inhibitory effects of CCRK knockdown on hepatic
tumorigenicity further provide proof-of-principle for the
development of selective small-molecule kinase inhibitors [34].
In conclusion, this study identiﬁes a novel molecular circuitry
that drives malignant progression and delineates the mechanistic
details of EZH2 bi-functionality as both transcriptional repressor
and co-activator in HCC. Exploiting these epigenetic vulnerabili-
ties via the CCRK signaling hub may offer unique potential for
HCC prevention and treatment.Financial support
This work was supported by the General Research Fund
(CUHK14102914, CUHK462710, CUHK462309), Health and
Medical Research Fund (01120216, 12110532, 09080042),
National Natural Science Foundation of China (373492), Focused
Investment Scheme – Scheme B (1907301) and Research
Fellowship Scheme of the Chinese University of Hong Kong.Conﬂict of interest
The authors who have taken part in this study declared that they
do not have anything to disclose regarding funding or conﬂict of
interest with respect to this manuscript.Author’s contributions
Study concept and design: J.J.Y.S., A.S.L.C.; acquisition of data:
H.F., Z.Y., Y.T., Y.-Y.L., M.S.L.; analysis and interpretation of data:
H.F., Y.T., A.S.L.C.; drafting of the manuscript: H.F., A.S.L.C.; critical
revision of the manuscript for important intellectual content:
P.B.S.L., A.M.L.C., K.-F.T., H.L.Y.C., J.J.Y.S., A.S.L.C.; statistical
analysis: F.H., Z.Y.; obtained funding: H.L.Y.C., J.J.Y.S., A.S.L.C.;
administrative, technical, or material support: Y.-S.C., P.B.S.L.,
A.M.L.C., K.-F.T.; study supervision: J.J.Y.S., A.S.L.C.Acknowledgements
This work was supported by the General Research Fund
(CUHK14102914, CUHK462710, CUHK462309), Health and
Medical Research Fund (01120216, 12110532, 09080042),
National Natural Science Foundation of China (373492), Focused
Investment Scheme – Scheme B (1907301) and Research
Fellowship Scheme of the Chinese University of Hong Kong.1110 Journal of Hepatology 2015Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.jhep.2014.11.
040.References
[1] El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma.
Gastroenterology 2012;142:e1261.
[2] Tian Y, Wong VW, Chan HL, Cheng AS. Epigenetic regulation of hep-
atocellular carcinoma in non-alcoholic fatty liver disease. Semin Cancer Biol
2013;23:471–482.
[3] Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma.
Gastroenterology 2011;140:1410–1426.
[4] Villanueva A, Llovet JM. Liver cancer in 2013: mutational landscape of HCC–
the end of the beginning. Nat Rev Clin Oncol 2014;11:73–74.
[5] Han ZG. Functional genomic studies: insights into the pathogenesis of liver
cancer. Annu Rev Genomics Hum Genet 2012;13:171–205.
[6] Yu Z, Cheng AS. Epigenetic deregulation of microRNAs: new opportunities to
target oncogenic signaling pathways in hepatocellular carcinoma. Curr
Pharm Des 2013;19:1192–1200.
[7] Zender L, Villanueva A, Tovar V, Sia D, Chiang DY, Llovet JM. Cancer gene
discovery in hepatocellular carcinoma. J Hepatol 2010;52:921–929.
[8] Hoshida Y, Nijman SM, Kobayashi M, Chan JA, Brunet JP, Chiang DY, et al.
Integrative transcriptome analysis reveals common molecular subclasses of
human hepatocellular carcinoma. Cancer Res 2009;69:7385–7392.
[9] Stauffer JK, Scarzello AJ, Andersen JB, De Kluyver RL, Back TC, Weiss JM, et al.
Coactivation of AKT and beta-catenin in mice rapidly induces formation of
lipogenic liver tumors. Cancer Res 2011;71:2718–2727.
[10] Knudsen ES, Gopal P, Singal AG. The changing landscape of hepatocellular
carcinoma: etiology, genetics, and therapy. Am J Pathol 2014;184:574–583.
[11] Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz Jr LA, Kinzler KW.
Cancer genome landscapes. Science 2013;339:1546–1558.
[12] You JS, Jones PA. Cancer genetics and epigenetics: two sides of the same
coin? Cancer Cell 2012;22:9–20.
[13] Zhang Z. Genomic landscape of liver cancer. Nat Genet 2012;44:1075–1077.
[14] Margueron R, Reinberg D. The Polycomb complex PRC2 and its mark in life.
Nature 2011;469:343–349.
[15] Tsang DP, Cheng AS. Epigenetic regulation of signaling pathways in cancer:
role of the histone methyltransferase EZH2. J Gastroenterol Hepatol
2011;26:19–27.
[16] Suva ML, Riggi N, Bernstein BE. Epigenetic reprogramming in cancer. Science
2013;339:1567–1570.
[17] Ma WL, Lai HC, Yeh S, Cai X, Chang C. Androgen receptor roles in
hepatocellular carcinoma, fatty liver, cirrhosis and hepatitis. Endocr Relat
Cancer 2014;21:R165–R182.
[18] Feng H, Cheng AS, Tsang DP, Li MS, Go MY, Cheung YS, et al. Cell cycle-
related kinase is a direct androgen receptor-regulated gene that drives beta-
catenin/T cell factor-dependent hepatocarcinogenesis. J Clin Invest
2011;121:3159–3175.
[19] Yu Z, Gao YQ, Feng H, Lee YY, Li MS, Tian Y, et al. Cell cycle-related kinase
mediates viral-host signalling to promote hepatitis B virus-associated
hepatocarcinogenesis. Gut 2014;63:1793–1804.
[20] Cheng AS, Lau SS, Chen Y, Kondo Y, Li MS, Feng H, et al. EZH2-mediated
concordant repression of Wnt antagonists promotes beta-catenin-depen-
dent hepatocarcinogenesis. Cancer Res 2011;71:4028–4039.
[21] Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K. EZH2 is
downstream of the pRB-E2F pathway, essential for proliferation and
ampliﬁed in cancer. EMBO J 2003;22:5323–5335.
[22] Kim E, KimM,Woo DH, Shin Y, Shin J, Chang N, et al. Phosphorylation of EZH2
activates STAT3 signaling via STAT3 methylation and promotes tumorigenic-
ity of glioblastoma stem-like cells. Cancer Cell 2013;23:839–852.
[23] Xu K, Wu ZJ, Groner AC, He HH, Cai C, Lis RT, et al. EZH2 oncogenic activity in
castration-resistant prostate cancer cells is Polycomb-independent. Science
2012;338:1465–1469.
[24] Lee JS, Chu IS, Mikaelyan A, Calvisi DF, Heo J, Reddy JK, et al. Application of
comparative functional genomics to identify best-ﬁt mouse models to study
human cancer. Nat Genet 2004;36:1306–1311.
[25] Awuah PK, Monga SP. Cell cycle-related kinase links androgen receptor and
beta-catenin signaling in hepatocellular carcinoma: why are men at a loss?
Hepatology 2012;55:970–973.vol. 62 j 1100–1111
JOURNAL OF HEPATOLOGY
[26] Li Z, Tuteja G, Schug J, Kaestner KH. Foxa1 and Foxa2 are essential for sexual
dimorphism in liver cancer. Cell 2012;148:72–83.
[27] Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, et al. Gender
disparity in liver cancer due to sex differences in MyD88-dependent IL-6
production. Science 2007;317:121–124.
[28] Hatziapostolou M, Polytarchou C, Aggelidou E, Drakaki A, Poultsides GA,
Jaeger SA, et al. An HNF4alpha-miRNA inﬂammatory feedback circuit
regulates hepatocellular oncogenesis. Cell 2011;147:1233–1247.
[29] Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NF-kappaB,
Lin28, Let-7 MicroRNA, and IL6 links inﬂammation to cell transformation.
Cell 2009;139:693–706.
[30] Yap TA, Omlin A, de Bono JS. Development of therapeutic combinations
targeting major cancer signaling pathways. J Clin Oncol 2013;31:1592–1605.Journal of Hepatology 2015[31] Cha TL, Zhou BP, Xia W, Wu Y, Yang CC, Chen CT, et al. Akt-mediated
phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3.
Science 2005;310:306–310.
[32] Ng SS, Cheung YT, An XM, Chen YC, Li M, Li GH, et al. Cell cycle-related
kinase: a novel candidate oncogene in human glioblastoma. J Natl Cancer
Inst 2007;99:936–948.
[33] He G, Dhar D, Nakagawa H, Font-Burgada J, Ogata H, Jiang Y, et al.
Identiﬁcation of liver cancer progenitors whose malignant progression
depends on autocrine IL-6 signaling. Cell 2013;155:384–396.
[34] Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase
inhibitors. Nat Rev Cancer 2009;9:28–39.vol. 62 j 1100–1111 1111
